Orphan Drugs in Surgery
Open Access
|Sep 2013References
- 1. Bignami F. Eurordis survey on orphan drugs availability in Europe // 6th Eurordis Round Table of Companies Workshop, Barcelona, Spain, 2007 (http://www.eurordis.org/IMG/pdf/2007ODsurvey-eurordis.pdf, accessed 05.04.2013.)
- 2. Boon W, Moors E. Exploring emerging technologies using metaphors-a study of orphan drugs and pharmacogenomics // Soc Sci Med, 2008; 66:1915-1927
- 3. Cito! // Newsletter of State Agency of Medicines of Latvia (Zāļu valsts aģentūras informatīvs izdevums), 2012; 1(48):7-9 (http://www.zva.gov.lv/doc_upl/ cito-nr48-web.pdf, accessed 05.04.2013.)
- 4. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe’s challenges // Commission of the European Communities, Brussels, 2008 (http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf, accessed 05.04.2013.)
- 5. Council Recommendation of 8 June 2009 on an action in the field of rare diseases // Official Journal of the European Communities, 2009; C151:7-10 (http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:EN:PDF, accessed 05.04.2013.)
- 6. de Varax A, Letellier M, Börtlein G. Study on orphan drugs: Phase I: overview of the conditions for marketing orphan drugs in Europe // Alcimed, Paris, France, 2004 (http://ec.europa.eu/health/files/orphanmp/doc/pricestudy/final_final_report_part_1_wwe_en.pdf, accessed 05.04.2013.)
- 7. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets // Health Policy, 2010; 97:173-179
- 8. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013 // J Med Econ, 2010; 13(2):295-301
- 9. Drug Register of the Republic of Latvia, 2013 (Latvijas Republikas Zāļu reģistrs 2013) // State Agency of Medicines of Latvia, Riga, 2013 (Rīga. Zāļu valsts aģentūra, 2013) (http://www.zva. gov.lv/?id=375&sa=375&top=334, accessed 05.04.2013.)
- 10. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs // Int J Technol Assess Health Care, 2007; 23(1):36-42
- 11. Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: The case of Bulgaria // Health Policy, 2012; 108:10-18
- 12. Le Cam Y. Inventory of access and prices of orphan drugs across Europe: a collaborative work between national alliances on rare diseases & Eurordis // Eurordis, Paris, France, 2010 (http://img.eurordis.org/newsletter/pdf/mar-2011/ERTC_13122010_ YLeCam_Final.pdf, accessed 05.04.2013.)
- 13. List of rare disease designations // European Medicines Agency (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/orphan_searse.jsp&mid=WC0b01ac058001d12b, accessed 05.04.2013.)
- 14. Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues // Expert Rev Pharmacoecon Outcomes Res, 2012; 12(1):23-29
- 15. National Plan for Rare Diseases in Latvia in 2012-2015 (Nacionālais plāns reto slimību jomā Latvijā 2012.-2015.gads) // Document of working group of Ministry of Health, Riga, 2011 (Rīga. Veselības Ministrijas darba grupas dokuments, 2011) (http://phoebe.vm.gov.lv/misc_db/web.nsf/626e6035eadbb4cd85256499006b15a6/ab77e1a6c33b637dc22573d800293aaa/$FILE/reto_ricibas_plans_projkets.pdf, accessed 05.04.2013.)
- 16. Order of reimbursement of medicines and medical devices for outpatient treatment (Ambulatorajai ārstēšanai paredzēto zāļu un medicīnisko ierīču iegādes izdevumu kompensācijas kārtība) // Regulation No. 899 of the Cabinet of Ministers, Riga, 2006 (version of 01.04.2013) (Rīga. Ministru kabineta noteikumi Nr.899, 2006) (redakcija uz 01.04.2013) (http://www.likumi.lv/doc.php?id=147522&from=off, accessed 05.04.2013.)
- 17. Orofino J, Soto J, Casado MA, Oyagüez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007 // Appl Health Econ Health Policy, 2010; 8(5):301-315
- 18. Pavlović N, Stanimirov B, Stojančević M, Paut- Kusturica M, Stoimenova A, Goločorbin-Kon S, Mikov M. An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden // Biotechnol Biotec Eq, 2012; 26(5):3236-3241
- 19. Picavet E, Dooms M, Cassiman D, Simoens S. Drugs for rare diseases: influence of orphan designation status on price // Appl Health Econ Health Policy, 2011; 9(4):275-279
- 20. Register of designated orphan medicinal products // European Commission (http://ec.europa.eu/health/documents/community-register/html/alforphreg.htm, accessed 05.04.2013.)
- 21. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products // Official Journal of the European Communities, 2000; L18:1-5 (http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF, accessed 05.04.2013.)
- 22. Reimbursement drug list, 2013 (Kompensējamo zāļu saraksts 2013) // National Health Service, Riga, 2013 (Rīga. Nacionālais veselības dienests, 2013) (http://www.vmnvd.gov.lv/lv/kompensejamiemedikamenti/kompensejamo-zalu-saraksts, accessed 05.04.2013.)
- 23. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020 // Orphanet J Rare Dis, 2011; 6(62):1-10
- 24. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency // Orphanet J Rare Dis, 2011; 6(42):1-8
- 25. Spokiene I. Legal assessment of current situation on orphan patients in Lithuania // Medicina (Kaunas), 2008; 44(8):571-576
Language: English
Page range: 57 - 62
Published on: Sep 5, 2013
Published by: Riga Stradins University
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2013 Konstantins Logviss, Dainis Krievins, Santa Purvina, published by Riga Stradins University
This work is licensed under the Creative Commons License.